Genovis Revenue and Competitors
Estimated Revenue & Valuation
- Genovis's estimated annual revenue is currently $4.9M per year.
- Genovis's estimated revenue per employee is $112,000
Employee Data
- Genovis has 44 Employees.
Genovis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Senior Production Scientist | Reveal Email/Phone |
3 | Production Technician | Reveal Email/Phone |
4 | Business Development Manager | Reveal Email/Phone |
5 | Senior Application Scientist | Reveal Email/Phone |
Genovis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.6M | 90 | -36% | $14.1M | N/A |
#2 | $83.2M | 468 | -3% | $251M | N/A |
#3 | $14M | 100 | 1% | N/A | N/A |
#4 | $14.6M | 0 | N/A | $12.5M | N/A |
#5 | $30.3M | 197 | -6% | N/A | N/A |
#6 | $0.1M | 6 | -25% | $2.6M | N/A |
#7 | $45.1M | 293 | 2% | N/A | N/A |
#8 | $4.8M | 43 | -7% | N/A | N/A |
#9 | $399.3M | 2037 | 40% | N/A | N/A |
#10 | $44M | 286 | 4% | N/A | N/A |
What Is Genovis?
Genovis offers a unique range of rapid and easy to use enzymatic tools primarily for the biopharmaceutical industry. Available worldwide, these SmartEnzymesâ„¢ are supplied in innovative formats for the development, production and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars and bispecifics. The Genovis SmartEnzymes are widely used for the digestion, de-glycosylation and conjugation of the target molecule and are an ideal companion to popular analytical techniques like LC-MS. Within the portfolio there are enzymes specific for: IgG digestion - FabRICATORâ„¢, FabALACTICAâ„¢, GingisKHANâ„¢, FabULOUSâ„¢ & FabRICATOR Zâ„¢ General proteolysis - GingisREXâ„¢ De-glycosylation and conjugation of IgGs - GlycINATORâ„¢, IgGZEROâ„¢ and GlyCLICKâ„¢ O-glycan analysis - OglyZORâ„¢, OpeRATORâ„¢, GlycOCATCHâ„¢ and SialEXOâ„¢
keywords:N/A
N/A
Total Funding
44
Number of Employees
$4.9M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Genovis News
Genovis, som marknadsför enzymer, antikroppar och reagenser för läkemedelsforskning och diagnostik, redovisar ett ebitda-resultat på 11,7...
Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company's Certified Adviser, certifiedadviser penser.
Other Companies in Lund
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 45 | 181% | N/A |
#2 | N/A | 45 | 32% | N/A |
#3 | $5M | 45 | 0% | N/A |
#4 | $8.2M | 45 | 55% | N/A |
#5 | $5.5M | 47 | -24% | N/A |